SCHEMBL1799198

SCHEMBL1799198

COC(=O)c1ccc(CN2C(=O)C(C(C)C)NC23CCN(C(=O)CC(C)(C)C)CC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CRBN Q96SW2 1/20 0.36
CXCR3 P49682 1/20 0.36
CHKA P35790 1/20 0.36
MDM2 Q00987 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHRM4 P08173 1/20 0.35
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
CYP11B2 P19099 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798684 0.82 NAMPT (0.40) LMNANPC1HTTRAB9AKDM4E
SCHEMBL3928978 0.82 LMNA (0.41) LMNANPC1HTTRAB9AKDM4E
SCHEMBL3914913 0.81 GAA (0.41) LMNANPC1HTTRAB9AKDM4E
SCHEMBL3916498 0.81 GAA (0.44) LMNANPC1HTTRAB9AKDM4E
SCHEMBL3926266 0.80 MAPT (0.47) LMNANPC1HTTRAB9AKMT2A
SCHEMBL3916428 0.80 KDM4E (0.42) LMNANPC1HTTRAB9AKDM4E
SCHEMBL3918951 0.80 LMNA (0.44) LMNANPC1HTTRAB9AKDM4E
SCHEMBL1800776 0.80 GPR183 (0.42) LMNANPC1HTTRAB9AOPRD1
SCHEMBL3915520 0.80 HRH3 (0.48) LMNANPC1HTTRAB9AKMT2A
SCHEMBL1799799 0.79 CYP2C19 (0.41) LMNANPC1HTTRAB9AOPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 LMNA 3374/4885NPC1 479/4885HTT 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.